07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Clinical News

Pivlaz clazosentan: Phase III started

ATLN began the double-blind, international Phase III CONSCIOUS-2 trial to compare 5 mg/hour Pivlaz vs. placebo in >765 patients who have had their aneurysm secured via surgery. The milestone triggers a CHF15 million payment to...
07:00 , Jun 26, 2006 |  BioCentury  |  Finance

What Actelion's investors want

Disappointing preliminary data from Actelion Ltd. 's Phase III CONSCIOUS-1 trial of clazosentan might re-open a debate on whether the European bellwether needs to fill its mid- to late-stage pipeline gap through in-licensing or M&A....
07:00 , Aug 15, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week's IPO by Coley (COLY) was the first U.S. biotech IPO to price at the top of the range and then trade up in the aftermarket since small molecule company Theravance (THRX) in October...
08:00 , Dec 22, 2004 |  BC Extra  |  Clinical News

Actelion starts Phase IIb/III cerebral vasospasm

Actelion (SWX:ATLN) started the international Phase IIb/III CONSCIOUS-1 trial of clazosentan to prevent cerebral vasospasm following subarachnoid hemorrhage (SAH), as measured by angiography. Secondary endpoints of the double-blind, placebo-controlled trial will include mortality and morbidity....
08:00 , Nov 15, 2004 |  BioCentury  |  Strategy

Facing a verity

Actelion Ltd. doesn't know why Veletri tezosentan failed in the Phase III VERITAS 1 and 2 trials, the company's second set of Phase III studies for acute heart failure (AHF). However, the failure means that...
08:00 , Nov 8, 2004 |  BC Extra  |  Clinical News

Actelion falls on Veletri failure

Actelion (SWX:ATLN) was down CHF37.50 (25%) to CHF115.50 on Monday after announcing that it halted its Phase III VERITAS 1 and 2 trials of Veletri tezosentan to treat acute heart failure (AHF). ATLN stopped the...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Back to School: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
08:00 , Mar 8, 2004 |  BioCentury  |  Finance

Ebb & Flow

With two months of the year already gone, the trends are saying that the IPO window is helping to open venture purse strings. In the U.S., private companies raised $641 million to the end of...
08:00 , Nov 3, 2003 |  BioCentury  |  Product Development

Actelion's milestone update

Actelion's milestone update Compound Indication Status Milestone Tracleer Pulmonary arterial hypertension (PAH) Mkt Zavesca Type 1 Gaucher's disease Mkt Tracleer Class II PAH Ph III EARLY Start 2Q04; data 3Q05 Tracleer Ischemic digital ulcers Ph...